

# EACTS 2020 Edwards Lifesciences Satellite Symposium



## Treatment of aortic stenosis: new learnings for the decade

Friday October 9<sup>th</sup> 2020 – 13:15-14:30

EACTS Virtual Platform / Hall A / Room 116-117

### Virtual Symposium

**Chairman: José L. Pomar**

*Hospital Clinic i Provincial  
de Barcelona (Spain)*

Place of surgical AVR in octogenarians and  
nonagenarians in 2020: state of the art.

**Krzysztof Bartus**

*Jagiellonian University, Department of  
Cardiovascular and Transplant Surgery,  
John Paul II Hospital, Krakow (Poland)*

Structural valve deterioration.  
What is the next step after VARC 2 guidelines.

**Philippe Pibarot**

*Quebec Heart and Lung Institute,  
Quebec (Canada)*

Prevention of thromboembolic events following AVR:  
aspirin/anti vitamin K/NOAC. Where are we standing?

**Nikolaos Bonaros**

*Cardiac Surgery Innsbruck  
Medical University (Austria)*

INSPIRIS RESILIA aortic valve:  
a clinical body of evidence.

**Martin Andreas**

*Medical University of  
Vienna (Austria)*

For professional use. For a listing of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the Instructions for Use (consult [eifu.edwards.com](http://eifu.edwards.com) where applicable).

Edwards devices placed on the European market meeting the essential requirements referred to in Article 3 of the Medical Device Directive 93/42/EEC bear the CE marking of conformity.

Edwards, Edwards Lifesciences, the stylized E logo, INSPIRIS, INSPIRIS RESILIA and RESILIA are trademarks or service marks of Edwards Lifesciences Corporation. All other trademarks are property of their respective owners.

© 2020 Edwards Lifesciences Corporation. All rights reserved. PP--EU-0756 v1.0

Edwards Lifesciences • Route de l'Etraz 70, 1260 Nyon, Switzerland • [edwards.com](http://edwards.com)



**Edwards**